Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials
Josep M Llovet, Amit G Singal, Augusto Villanueva, Richard S Finn, Masatoshi Kudo, Peter R Galle, Masafumi Ikeda, Sophie Callies, Louise M McGrath, Chunxiao Wang, Paolo Abada, Ryan C Widau, Elena Gonzalez-Gugel, Andrew X Zhu, Josep M Llovet, Amit G Singal, Augusto Villanueva, Richard S Finn, Masatoshi Kudo, Peter R Galle, Masafumi Ikeda, Sophie Callies, Louise M McGrath, Chunxiao Wang, Paolo Abada, Ryan C Widau, Elena Gonzalez-Gugel, Andrew X Zhu
Abstract
Purpose: Ramucirumab is an effective treatment for patients with advanced hepatocellular carcinoma (aHCC) and baseline alpha-fetoprotein (AFP) ≥400 ng/mL. We aimed to identify prognostic and predictive factors of response to ramucirumab in patients with aHCC with AFP ≥400 ng/mL from the phase III REACH and REACH-2 randomized trials.
Patients and methods: Patients with aHCC, Child-Pugh class A with prior sorafenib treatment were randomized in REACH and REACH-2 (ramucirumab 8 mg/kg or placebo, biweekly). Meta-analysis of individual patient-level data (pooled population) from REACH (AFP ≥400 ng/mL) and REACH-2 was performed. A drug exposure analysis was conducted for those with evaluable pharmacokinetic data. To identify potential prognostic factors for overall survival (OS), multivariate analyses were performed using a Cox proportional hazards regression model. To define predictors of ramucirumab benefit, subgroup-by-treatment interaction terms were evaluated.
Results: Of 542 patients (316 ramucirumab, 226 placebo) analyzed, eight variables had independent prognostic value associated with poor outcome (geographical region, Eastern Cooperative Oncology Group performance score ≥1, AFP >1,000 ng/mL, Child-Pugh >A5, extrahepatic spread, high neutrophil-to-lymphocyte ratio, high alkaline phosphatase and aspartate aminotransferase). Ramucirumab survival benefit was present across all subgroups, including patients with very aggressive HCC [above median AFP; HR: 0.64; 95% confidence interval (CI): 0.49-0.84] and nonviral aHCC (HR: 0.56; 95% CI: 0.40-0.79). While no baseline factor was predictive of a differential OS benefit with ramucirumab, analyses demonstrated an association between high drug exposure, treatment-emergent hypertension (grade ≥3), and increased ramucirumab benefit.
Conclusions: Ramucirumab provided a survival benefit irrespective of baseline prognostic covariates, and this benefit was greatest in patients with high ramucirumab drug exposure and/or those with treatment-related hypertension.
Trial registration: ClinicalTrials.gov NCT01140347 NCT02435433.
©2022 The Authors; Published by the American Association for Cancer Research.
Figures
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
- Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. . Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6.
- Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599–616.
- American Cancer Society. Global cancer facts and figures. 4th ed. Atlanta: American Cancer Society; 2018.
- Brunetti O, Gnoni A, Licchetta A, Longo V, Calabrese A, Argentiero A, et al. . Predictive and prognostic factors in HCC patients treated with sorafenib. Medicina 2019;55:707.
- Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, et al. . Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis. Cancer Med 2019;8:3719–28.
- Teufel M, Seidel H, Kochert K, Meinhardt G, Finn RS, Llovet JM, et al. . Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology 2019;156:1731–41.
- Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 2017;67:999–1008.
- Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, et al. . Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197–215 second-line study for advanced hepatocellular carcinoma. Oncotarget 2017;8:14408–15.
- Villanueva A, Llovet JM. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res 2012;18:1824.
- Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. . A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 2012;57:1013–20.
- Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liv Int 2019;39:2008–23.
- Meyer T, Kelley R, Mangeshkar M, Cheng AL, El-Khoueiry A, Abou-Alfa G. 749P Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:v287–88.
- Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, et al. . Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer 2021;124:1388–97.
- Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, et al. . Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol 2013;11:306.
- Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al. . Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010;15:85–92.
- Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, et al. . Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 2017;16:2215–22.
- Nguyen L, Chapel S, Tran BD, Lacy S. Cabozantinib exposure–response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. J Pharmacokinet Pharmacodyn 2019;46:577–89.
- Zhu AX, Park JO, Ryoo B-Y, Yen C-J, Poon R, Pastorelli D, et al. . Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859–70.
- Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20:282–96.
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245–55.
- Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, et al. . Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta 2016;463:39–44.
- Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, et al. . Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016;22:262–74.
- Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol 2013;31:2963–9.
- O'Brien L, Westwood P, Gao L, Heathman M. Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. Br J Clin Pharmacol 2017;83:2741–51.
- Liu C, Yu J, Li H, Liu J, Xu Y, Song P, et al. . Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther 2017;101:657–66.
- Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. . NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450–6.
- Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet North Am Ed 2017;389:56–66.
- Tyson GL, Duan Z, Kramer JR, Davila JA, Richardson PA, El-Serag HB. Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9:989–94.
- Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. . Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509–16.
- Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. . Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54–63.
- Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E, et al. . Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget 2016;7:15243–51.
- Kudo M, Ikeda M, Galle PR, Yamashita T, Finn RS, Liang K, et al. . Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes by treatment-emergent ascites. Hepatol Res 2021;51:715–21.
- Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, et al. . Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget 2016;7:67142–9.
- Qi X, Li J, Deng H, Li H, Su C, Guo X. Neutrophil-to-lymphocyte ratio for the prognostic assessment of hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Oncotarget 2016;7:45283–301.
- Xue T-C, Zhang L, Xie X-Y, Ge N-L, Li L-X, Zhang B-H, et al. . Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS One 2014;9:e96072.
- Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma. Ann Hepatol 2021;22:100249.
- Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
- Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol 2016;8:421–38.
- Negro F. Natural history of NASH and HCC. Liver Int 2020;40:72–6.
- Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. . CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:v874–v5.
- Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. . Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77–90.
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. . Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–905.
- Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. . Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193–202.
- Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, et al. . Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: impact of liver disease etiology. Liver Int 2021;41:2759–97.
- Touyz RM, Lang NN. Hypertension and antiangiogenesis: the janus face of VEGF inhibitors. JACC CardioOncol 2019;1:37–40.
- Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. . Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18:273–80.
- Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 2011;117:c312–9.
- Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–73.
- Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, et al. . Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 2015;10:e0116527.
- Dionisio de Sousa IJ, Casalta-Lopes J, Rodrigues J, Pais A, Bonito N, Jacinto PS, et al. . Association between bevacizumab-related hypertension and response to treatment in metastatic colorectal cancer patients. J Clin Oncol 33:15s, 2015. (suppl; abstr e14636).
- Kudo M. Better efficacy of ramucirumab in Japanese patients than in the global population with unresectable hepatocellular carcinoma. Liver Cancer 2020;9:232–44.
- Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, et al. . Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer 2021;157:140–52.
- Rimola J, Diaz-Gonzalez A, Darnell A, Varela M, Pons F, Hernandez-Guerra M, et al. . Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events. Hepatology 2018;67:612–22.
Source: PubMed